An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy

Cancer

Volumn 118, Issue 24, 2012, Pages 6063-6071

  Antonarakis, Emmanuel S ^a   Keizman, Daniel ^a   Zhang, Zhe ^a   Gurel, Bora ^a   Lotan, Tamara L ^a   Hicks, Jessica L ^a   Fedor, Helen L ^a   Carducci, Michael A ^a   De Marzo, Angelo M ^a   Eisenberger, Mario A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

adjuvant docetaxel; high risk prostate cancer; Ki67; MYC; prognostic model; progression free survival; PTEN

Indexed keywords

DOCETAXEL; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; PROTEIN P53; PROTEIN S6; TRANSCRIPTION FACTOR ERG;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DRUG RESPONSE; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; PTEN PHOSPHOHYDROLASE; SURVIVAL RATE; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84870659824     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27689     Document Type: Article

References (36)

1. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-236.
2. Han M, Partin AW, Piantadosi S, et al. Era-specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001; 166: 416-419.
3. Zietman AL, Coen JJ, Dallow KC, Shipley WU,. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys. 1995; 32: 287-292.
4. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004; 172: 910-914.
5. Eastham JA, Kelly WK, Grossfeld GD, et al. CALGB 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003; 62S: 55-62.
6. Fizazi K, Lesaunier F, Delva R, et al. Docetaxel-estramustine in high-risk localized prostate cancer: first results of the French Genitourinary Tumor Group phase III trial (GETUG 12) [abstract]. J Clin Oncol. 2011; 29 (suppl 67). Abstract 4513.
7. Netto GJ, Eisenberger M, Epstein JI, et al. Interobserver variability in histologic evaluation of radical prostatectomy between central and local pathologists: findings of TAX3501 multinational clinical trial. Urology. 2011; 77: 1155-1160.
8. Kellokumpu-Lehtinen P, Hjelm-Eriksson M, Thellenberg-Karlsson C, et al. High toxicity in patients receiving adjuvant docetaxel plus hormone treatment after radical radiotherapy for high-risk prostate cancer: a preplanned safety report of SPCG 13 trial [abstract]. J Clin Oncol. 2011; 29 (suppl 7). Abstract 63.
9. Montgomery B, Lavori P, Garzotto M, et al. Veterans Affairs Cooperative Studies Program study 553: chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology. 2008; 72: 474-480.
10. Maehama T, Dixon JE,. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol-3,4,5-triphosphates. J Biol Chem. 1998; 273: 13375-13378.
11. Li L, Ittmann MM, Ayala G, et al. The emerging role of the PI3K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8: 108-118.
12. Guertin DA, Sabatini DM,. Defining the role of mTOR in cancer. Cancer Cell. 2007; 12: 9-22.
13. Yoshimoto M, Cutz JC, Nuin PA, et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet. 2006; 169: 128-137.
14. Yoshimoto M, Ludkovski O, Degrace D, et al. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer. 2012; 51: 149-160.
15. Lotan TL, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high-risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011; 17: 6563-6573.
16. Bedolla R, Prihoda TJ, Kreisberg JI, et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res. 2007; 13: 3860-3867.
17. Priulla M, Calastretti A, Bruno P, et al. Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. Prostate. 2007; 67: 782-789.
18. Kibel AS, Rosenbaum E, Kattan MW, et al. Adjuvant weekly docetaxel for patients with high-risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007; 177: 1777-1781.
19. Gurel B, Iwata T, Koh CM, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008; 21: 1156-1167.
20. Koh CM, Gurel B, Sutcliffe S, et al. Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. Am J Pathol. 2011; 178: 1824-1834.
21. Tomlins SA, Mehra R, Rhodes DR, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310: 644-648.
22. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010; 13: 228-237.
23. Chaux A, Albadine R, Toubaji A, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol. 2011; 35: 1014-1020.
24. van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011; 24: 1128-1138.
25. Roberts WW, Bergstralh EJ, Blute ML, et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001; 57: 1033-1037.
26. Fedor HL, De Marzo AM,. Practical methods for tissue microarray construction. Methods Mol Med. 2005; 103: 89-101.
27. Schultz L, Chaux A, Albadine R, et al. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol. 2011; 35: 1549-1556.
28. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994; 331: 1259-1264.
29. Wang SI, Parsons R, Ittmann M,. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res. 1998; 4: 811-815.
30. Pinhel IF, Macneill FA, Hills MJ, et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res. 2010; 12: R76.
31. Vivanco I, Palaskas N, Tran C, et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell. 2007; 11: 555-569.
32. Mulholland DJ, Tran LM, Li Y, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011; 19: 792-804.
33. Meyer N, Penn LZ,. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8: 976-990.
34. Kurosumi M, Tabei T, Sano M, et al. Relationship between the signal ratios of HER-2/CEP17 and c-MYC/CEP17 and the pathological response of neoadjuvant therapy using docetaxel and trastuzumab in breast cancer. Mol Med Rep. 2008; 1: 71-75.
35. Salter KH, Acharya CR, Walters KS, et al. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One. 2008; 3: e1908.
36. Geng H, Rademacher BL, Pittsenbarger J, et al. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res. 2010; 70: 3239-3248.